相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
Theresa E. Hickey et al.
NATURE MEDICINE (2021)
Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype
Damir Vareslija et al.
ONCOGENE (2021)
The Metabolic Mechanisms of Breast Cancer Metastasis
Lingling Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 Fusion
Jae Heon Jeong et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+Breast Cancer
Javier A. Menendez et al.
CANCERS (2021)
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Aditya Bardia et al.
CLINICAL CANCER RESEARCH (2021)
A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer Metastasis
Rebecca J. Watters et al.
ENDOCRINOLOGY (2021)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Aftimos et al.
CANCER DISCOVERY (2021)
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2021)
Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects
Spencer Arnesen et al.
CANCER RESEARCH (2021)
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer
Balkees Abderrahman et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
Meenakshi Anurag et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage
Shiyi Yu et al.
CELLULAR ONCOLOGY (2020)
Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
Dongbo Li et al.
CANCER SCIENCE (2020)
Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression
Max H. Kushner et al.
EMBO REPORTS (2020)
Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing
Ryan T. Davis et al.
NATURE CELL BIOLOGY (2020)
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
Guotai Xu et al.
NATURE GENETICS (2020)
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Lillian M. Smyth et al.
CANCER DISCOVERY (2020)
Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).
Seth Andrew Wander et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
Elgene Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation
Yan Zheng et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
Bruno M. Simoes et al.
ONCOGENE (2020)
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao et al.
CLINICAL CANCER RESEARCH (2020)
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy
Arkadiusz Z. Dudek et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges
David Barua et al.
CANCER LETTERS (2020)
Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance
Alex J. Gooding et al.
MOLECULAR CANCER RESEARCH (2020)
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
Susana Garcia-Recio et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells
Lama Hamadneh et al.
SCIENTIFIC REPORTS (2020)
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis
Alexandra Desnoyers et al.
CANCER TREATMENT REVIEWS (2020)
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Li Li et al.
BREAST CANCER RESEARCH (2020)
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets
Damir Vareslija et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets
Damir Vareslija et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
Ulrik Narbe et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells
Lotem Zinger et al.
CLINICAL CANCER RESEARCH (2019)
Non-canonical AR activity facilitates endocrine resistance in breast cancer
KeeMing Chia et al.
ENDOCRINE-RELATED CANCER (2019)
Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
Xiao Chu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4
Lana McClements et al.
BMC CANCER (2019)
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
Andrea DeCensi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers
Aurelien Linares et al.
MOLECULAR ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance
Eylem Kulkoyluoglu-Cotul et al.
CANCERS (2019)
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer
Joshua Z. Drago et al.
CLINICAL CANCER RESEARCH (2019)
Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Laura Creevey et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Matteo Morotti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer
Marina Bacci et al.
CELL REPORTS (2019)
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER plus advanced breast cancer
Aditya Bardia et al.
FUTURE ONCOLOGY (2019)
Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER plus breast cancer
Fatou Jallow et al.
ONCOGENE (2019)
Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
Diane M. Demas et al.
FRONTIERS IN ONCOLOGY (2019)
AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells
Francesca De Amicis et al.
BMC CANCER (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Sarah Croessmann et al.
CLINICAL CANCER RESEARCH (2019)
mTOR as a central hub of nutrient signalling and cell growth
Joungmok Kim et al.
NATURE CELL BIOLOGY (2019)
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
Utthara Nayar et al.
NATURE GENETICS (2019)
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
Xiaoyong Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER plus breast cancer models resistant to CDK4/6 inhibitors
Hitisha K. Patel et al.
BREAST CANCER RESEARCH (2019)
Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer
Sean W. Fanning et al.
ENDOCRINOLOGY (2019)
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
R. J. Hartmaier et al.
ANNALS OF ONCOLOGY (2018)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer
Rasmi R. Mishra et al.
CLINICAL CANCER RESEARCH (2018)
Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer
Elspeth Ward et al.
CLINICAL CANCER RESEARCH (2018)
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Marni B. Siegel et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Na Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Cancer Stem Cell Phenotypes in ERthorn Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes
Thu H. Truong et al.
MOLECULAR CANCER RESEARCH (2018)
The Unfolded Protein Response and Cell Fate Control
Claudio Hetz et al.
MOLECULAR CELL (2018)
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling
Pernilla Roswall et al.
NATURE MEDICINE (2018)
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer
Alacoque L. Browne et al.
ONCOGENE (2018)
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
Melanie Royce et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer
Subhamoy Dasgupta et al.
NATURE (2018)
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
Jonathan T. Lei et al.
CELL REPORTS (2018)
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
Kunihiko Hinohara et al.
CANCER CELL (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
Ang Gao et al.
NATURE COMMUNICATIONS (2018)
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Colt A. Egelston et al.
NATURE COMMUNICATIONS (2018)
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
Carla L. Alves et al.
BREAST CANCER RESEARCH (2018)
Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability
Wen-Shan Liu et al.
BREAST CANCER RESEARCH (2018)
Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer
Tian Du et al.
BREAST CANCER RESEARCH (2018)
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Sri Lakshmi Hyndavi Yeruva et al.
NPJ BREAST CANCER (2018)
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
John A. Katzenellenbogen et al.
NATURE REVIEWS CANCER (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
A. Harrod et al.
ONCOGENE (2017)
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Weiyi Toy et al.
CANCER DISCOVERY (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
Rinath Jeselsohn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
Jennifer M. Giltnane et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer
Jianbo Zhang et al.
CELL DEATH & DISEASE (2017)
Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
Federica Sotgia et al.
Oncotarget (2017)
Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis
Ming Yue et al.
CELL REPORTS (2017)
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Paule Augereau et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
S. Alkner et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases
Nolan Priedigkeit et al.
JCI INSIGHT (2017)
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani et al.
CLINICAL CANCER RESEARCH (2017)
Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles
Pasquale Sansone et al.
CANCER RESEARCH (2017)
Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer
Quyen Thu Bui et al.
CANCER LETTERS (2017)
Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors
Zhengzhi Zou et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes
Junjian Wang et al.
CANCER LETTERS (2016)
Cooperative Dynamics of AR and ER Activity in Breast Cancer
Nicholas C. D'Amato et al.
MOLECULAR CANCER RESEARCH (2016)
Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer
Stephanie Legare et al.
MOLECULAR ENDOCRINOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions
Elisa Fiorito et al.
NUCLEIC ACIDS RESEARCH (2016)
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
Xiaoyong Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
Renquan Lu et al.
NATURE COMMUNICATIONS (2016)
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer
Nyam-Osor Chimge et al.
NATURE COMMUNICATIONS (2016)
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI
Chengjian Mao et al.
SCIENTIFIC REPORTS (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer
Fanny Dupuy et al.
CELL METABOLISM (2015)
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
Suzanne E. Wardell et al.
ENDOCRINE-RELATED CANCER (2015)
Endocrine resistance in breast cancer - An overview and update
Robert Clarke et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Ricardo Ribas et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Progesterone receptor modulates ERα action in breast cancer
Hisham Mohammed et al.
NATURE (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Ana Bosch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1
Jie Ming et al.
ONCOTARGET (2015)
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
Bruno M. Simoes et al.
CELL REPORTS (2015)
Dense Collagen-I Matrices Enhance Pro-Tumorigenic Estrogen-Prolactin Crosstalk in MCF-7 and T47D Breast Cancer Cells
Craig E. Barcus et al.
PLOS ONE (2015)
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen- resistant breast cancer models, by reversing Bcl-2 overexpression
Paromita Raha et al.
BREAST CANCER RESEARCH (2015)
Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells
Jie Yuan et al.
BREAST CANCER RESEARCH (2015)
Slug Promotes Survival during Metastasis through Suppression of Puma-Mediated Apoptosis
Seaho Kim et al.
CANCER RESEARCH (2014)
Sox2 promotes tamoxifen resistance in breast cancer cells
Marco Piva et al.
EMBO MOLECULAR MEDICINE (2014)
MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer
Ayesha N. Shajahan-Haq et al.
MOLECULAR CANCER (2014)
Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
Amir T. Fathi et al.
ONCOLOGIST (2014)
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
Jamunarani Veeraraghavan et al.
NATURE COMMUNICATIONS (2014)
RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells
Maaike P. A. van Bragt et al.
ELIFE (2014)
The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer
Yan Ni Loh et al.
BMC CANCER (2013)
Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
R. A. McCloy et al.
BRITISH JOURNAL OF CANCER (2013)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility
Vasiliki Theodorou et al.
GENOME RESEARCH (2013)
HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2
Gauri J. Sabnis et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
A. Ward et al.
ONCOGENE (2013)
Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties
Xue Lin et al.
BREAST CANCER RESEARCH (2013)
The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin
Osvaldo Pontiggia et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
A. Dubrovska et al.
BRITISH JOURNAL OF CANCER (2012)
Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1
Jean McBryan et al.
CANCER RESEARCH (2012)
Glucose-Regulated Protein 78 Controls Cross-talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness
Katherine L. Cook et al.
CANCER RESEARCH (2012)
Endoplasmic Reticulum Stress, the Unfolded Protein Response, Autophagy, and the Integrated Regulation of Breast Cancer Cell Fate
Robert Clarke et al.
CANCER RESEARCH (2012)
Mechanisms of FGFR3 actions in endocrine resistant breast cancer
D. C. Tomlinson et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α
F. Vesuna et al.
ONCOGENE (2012)
A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
Emily M. Fox et al.
CANCER RESEARCH (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
Todd W. Miller et al.
CLINICAL CANCER RESEARCH (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
FOXA1 is a key determinant of estrogen receptor function and endocrine response
Antoni Hurtado et al.
NATURE GENETICS (2011)
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
Eric A. Ariazi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy
Laura Gonzalez-Malerva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Antiestrogens Induce Transforming Growth Factor β-Mediated Immunosuppression in Breast Cancer
Christian M. Joffroy et al.
CANCER RESEARCH (2010)
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Hannah Harrison et al.
CANCER RESEARCH (2010)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
Mathieu Lupien et al.
GENES & DEVELOPMENT (2010)
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers
Giampaolo Bianchini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
Arzu Umar et al.
MOLECULAR & CELLULAR PROTEOMICS (2009)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization
M. A. Qadir et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
Jozien Helleman et al.
CLINICAL CANCER RESEARCH (2008)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
Expression and splicing of the unfolded protein response gene XBP-1 are sieniticantly associated with clinical outcome of endocrine-treated breast cancer
Michael P. A. Davies et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways
Stephen Safe et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2008)
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
Antoni Hurtado et al.
NATURE (2008)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
Adaptation of energy metabolism in breast cancer brain metastases
Emily I. Chen et al.
CANCER RESEARCH (2007)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Qun Zhou et al.
CANCER BIOLOGY & THERAPY (2007)
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
A Sica et al.
EUROPEAN JOURNAL OF CANCER (2006)
Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation
S Hiscox et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1
JS Carroll et al.
CELL (2005)
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
AJ Butt et al.
ENDOCRINE-RELATED CANCER (2005)
Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT
EK Keeton et al.
MOLECULAR ENDOCRINOLOGY (2005)
c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells
S Mukherjee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
MC Gutierrez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mechanisms of estrogen receptor signaling:: Convergence of genomic and nongenomic actions on target genes
L Björnström et al.
MOLECULAR ENDOCRINOLOGY (2005)
Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
I Vergote et al.
BRITISH JOURNAL OF CANCER (2004)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Cyclin DI overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
M Stendahl et al.
BRITISH JOURNAL OF CANCER (2004)
Estrogen receptor corepressors - a role in human breast cancer?
KM Dobrzycka et al.
ENDOCRINE-RELATED CANCER (2003)
Estrogen receptor α, a molecular switch converting transforming growth factor-α-mediated proliferation into differentiation in neuroblastoma cells
P Ciana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Host microenvironment in breast cancer development - Epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland
SZ Haslam et al.
BREAST CANCER RESEARCH (2003)
Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation
H Lee et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mechanisms of disease - Production and actions of estrogens
CJ Gruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance
RA Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor
JF de Mora et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export
SH Hong et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
